BrightGene Bio Medical Technology C Cash Flow Conversion Efficiency
BrightGene Bio Medical Technology C cash flow conversion efficiency. Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) has a cash flow conversion efficiency ratio of 0.011x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥26.70 Million ≈ $3.91 Million USD) by net assets (CN¥2.35 Billion ≈ $344.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BrightGene Bio Medical Technology C (2016–2024)
Cash flow conversion efficiency of BrightGene Bio Medical Technology C from 2016 to 2024. This chart illustrates how BrightGene Bio Medical Technology C's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BrightGene Bio Medical Technology C share price for real-time trading data and today's change.
BrightGene Bio Medical Technology C Cash Flow Conversion Ratio Explained
BrightGene Bio Medical Technology C cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BrightGene Bio Medical Technology C Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BrightGene Bio Medical Technology C ranked by their cash flow conversion efficiency. Also see BrightGene Bio Medical Technology C market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lafarge Malayan Cement Bhd
KLSE:3794
|
0.039x |
|
Extendicare Inc
TO:EXE
|
0.146x |
|
Dongsuh
KO:026960
|
0.006x |
|
Twenty One Capital, Inc.
NYSE:XXI
|
N/A |
|
Boston Beer Company Inc
NYSE:SAM
|
0.112x |
|
DRDGOLD Limited
JSE:DRD
|
0.251x |
|
NBTM New Materials Group Co Ltd
SHG:600114
|
0.081x |
|
Shaanxi Ligeance Mineral Resources Co Ltd
SHE:000697
|
0.002x |
Annual Cash Flow Conversion Efficiency for BrightGene Bio Medical Technology C (2016–2024)
The table below shows the annual cash flow conversion efficiency of BrightGene Bio Medical Technology C from 2016 to 2024. Review free cash flow generation of BrightGene Bio Medical Technology C to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.44 Billion ≈ $356.66 Million |
CN¥245.56 Million ≈ $35.93 Million |
0.101x | +25.06% |
| 2023-12-31 | CN¥2.42 Billion ≈ $353.77 Million |
CN¥194.77 Million ≈ $28.50 Million |
0.081x | -41.98% |
| 2022-12-31 | CN¥2.24 Billion ≈ $328.03 Million |
CN¥311.26 Million ≈ $45.55 Million |
0.139x | +37.34% |
| 2021-12-31 | CN¥1.74 Billion ≈ $254.86 Million |
CN¥176.08 Million ≈ $25.77 Million |
0.101x | -6.82% |
| 2020-12-31 | CN¥1.43 Billion ≈ $209.63 Million |
CN¥155.43 Million ≈ $22.74 Million |
0.108x | +132.28% |
| 2019-12-31 | CN¥1.31 Billion ≈ $192.15 Million |
CN¥61.33 Million ≈ $8.98 Million |
0.047x | -43.58% |
| 2018-12-31 | CN¥772.85 Million ≈ $113.09 Million |
CN¥63.99 Million ≈ $9.36 Million |
0.083x | +3.25% |
| 2017-12-31 | CN¥446.02 Million ≈ $65.27 Million |
CN¥35.77 Million ≈ $5.23 Million |
0.080x | -40.63% |
| 2016-12-31 | CN¥220.15 Million ≈ $32.21 Million |
CN¥29.73 Million ≈ $4.35 Million |
0.135x | -- |
About BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also pr… Read more